Breaking News Instant updates and real-time market news.

ACHN

Achillion

$4.81

0.8 (19.95%)

07:59
08/10/17
08/10
07:59
08/10/17
07:59

Achillion price target raised to $7 from $5 at Maxim

Maxim analyst Jason Kolbert is introducing estimates for paroxysmal nocturnal hemoglobinuria in his model for Achillion after the company reported "proof of concept" news for its Factor D program. Adding in the potential for an eventual PHH indication leads him to raise his price target on Achillion shares to $7 from $5. He keeps a Buy rating on the stock.

ACHN Achillion
$4.81

0.8 (19.95%)

04/25/17
JMPS
04/25/17
NO CHANGE
JMPS
Johsnson &Johnson data positive for Achillion, says JMP Securities
JMP Securities analyst Liisa Bayko says that data on a triple combination HCV treatment presented by Johnson & Johnson (JNJ) yesterday is positive for Achillion (ACHN). The analyst noted that the triple combination includes Achillion's odalasvir and that the six week treatment regimen is shorter than the eight weeks required for Gilead's (GILD) Harvoni. The analyst says that Achillion's stock dropped sharply yesterday because there was disappointment over the combination's efficacy in genotype 3 patients. However, she says that such patients only represent 10% of the total, and she says that Achillion can "conservatively" obtain peak royalty revenue of about $100M from its drug. Bayko keeps a $13 price target and an Outperform rating on the shares.
04/25/17
MAXM
04/25/17
NO CHANGE
Target $5
MAXM
Buy
Achillion price target lowered to $5 from $8 at Maxim
Maxim analyst Jason Kolbert said phase 2 trial results demonstrated that Achillion's (ACHN) triple combination of simeprevir, odalasvir and AL-335 has the ability to shorten treatment duration, be generally well tolerated and offer high efficacy for hepatitis C virus genotype 1 patients. While Johnson & Johnson (JNJ) is likely to move forward with this regimen, allowing Achillion to realize milestones, Kolbert has removed any royalties from his model as he expects others to dominate the landscape with "near perfect" regimens. Kolbert lowered his price target on Achillion to $5 from $8 but keeps a Buy rating on the shares.
05/18/17
LEER
05/18/17
UPGRADE
Target $6
LEER
Outperform
Achillion upgraded to Outperform from Market Perform at Leerink
Leerink analyst Joseph Schwartz upgraded Achillion Pharmaceuticals (ACHN) and raised his price target for the shares to $6 from $4. The analyst sees limited downside from current share levels even if the complement study fails, assuming the hepatitis C virus partnership with Johnson & Johnson (JNJ) remains intact. Schwartz assigned a "conservative" 33% probability of success to Achillion's complement program due to the lack of precedent for an oral small molecule inhibitor of complement factor D that is selective enough to avoid off target effects. He believes risks to successful ACH-4471 development are fully discounted in Achillion's current stock price.
08/10/17
BARD
08/10/17
DOWNGRADE
BARD
Neutral
Achillion downgraded to Neutral from Outperform at Baird

TODAY'S FREE FLY STORIES

SIRI

SiriusXM

$5.40

0.02 (0.37%)

12:45
11/17/17
11/17
12:45
11/17/17
12:45
Options
Sirius XM call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
11/17/17
11/17
12:45
11/17/17
12:45
General news
Breaking General news story  »

Week of 11/17…

FL

Foot Locker

$39.80

7.95 (24.96%)

12:32
11/17/17
11/17
12:32
11/17/17
12:32
Upgrade
Foot Locker rating change  »

Deutsche sees sustained…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Nov

XRT

S&P Retail Index SPDR

$41.59

0.98 (2.41%)

12:30
11/17/17
11/17
12:30
11/17/17
12:30
Options
Defensive short-term play in SPDR Retail ETF »

Defensive short-term play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:30
11/17/17
11/17
12:30
11/17/17
12:30
General news
Breaking General news story  »

San Francisco Federal…

FTI

TechnipFMC

$26.72

0.175 (0.66%)

12:25
11/17/17
11/17
12:25
11/17/17
12:25
Options
FMC Technologies call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

$NSD

NASDAQ Market Internals

12:17
11/17/17
11/17
12:17
11/17/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$11.25

0.18 (1.63%)

12:16
11/17/17
11/17
12:16
11/17/17
12:16
Options
AMD calls outpace puts 4:1 as shares advance »

AMD calls outpace puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

TSLA

Tesla

$312.50

1.2 (0.39%)

, AMZN

Amazon.com

$1,137.29

10.6 (0.94%)

12:16
11/17/17
11/17
12:16
11/17/17
12:16
Hot Stocks
Tesla, Amazon look to shake up trucking industry with new vehicle, app »

Shares of third-party…

TSLA

Tesla

$312.50

1.2 (0.39%)

AMZN

Amazon.com

$1,137.29

10.6 (0.94%)

CHRW

C.H. Robinson

$80.40

0.45 (0.56%)

LSTR

Landstar System

$96.80

1.75 (1.84%)

XPO

XPO Logistics

$74.29

0.1035 (0.14%)

JBHT

J.B. Hunt

$102.98

1.44 (1.42%)

WMT

Wal-Mart

$96.94

-2.68 (-2.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Nov

  • 20

    Nov

  • 21

    Nov

  • 21

    Nov

  • 28

    Nov

  • 07

    Dec

  • 11

    Dec

  • 09

    Jan

  • 16

    Jan

  • 20

    Feb

  • 18

    Mar

$NYE

NYSE Market Internals

12:16
11/17/17
11/17
12:16
11/17/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDXG

MiMedx

$11.36

-0.58 (-4.86%)

12:12
11/17/17
11/17
12:12
11/17/17
12:12
Recommendations
MiMedx analyst commentary  »

MiMedx growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 30

    Nov

  • 01

    Dec

XOP

SPDR Oil Exploration and Production Fund

$34.83

0.525 (1.53%)

12:00
11/17/17
11/17
12:00
11/17/17
12:00
Options
Defensive short-term option play in SPDR Oil Exploration and Production ETF »

Defensive short-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNK

Teekay Tankers

$1.41

0.01 (0.71%)

11:55
11/17/17
11/17
11:55
11/17/17
11:55
Conference/Events
Teekay Tankers to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Nov

TWX

Time Warner

$88.53

0.52 (0.59%)

, VIA

Viacom

$30.10

-0.65 (-2.11%)

11:50
11/17/17
11/17
11:50
11/17/17
11:50
Hot Stocks
Box Office Battle: 'Justice League' to vanquish 'Thor' in debut »

The major release opening…

TWX

Time Warner

$88.53

0.52 (0.59%)

VIA

Viacom

$30.10

-0.65 (-2.11%)

VIAB

Viacom

$23.69

-0.92 (-3.74%)

LGF.A

Lionsgate

$32.32

1.28 (4.12%)

LGF.B

Lionsgate

$30.70

1.17 (3.96%)

DIS

Disney

$103.61

0.01 (0.01%)

FOX

21st Century Fox

$28.60

0.65 (2.33%)

FOXA

21st Century Fox

$29.32

0.59 (2.05%)

CMCSA

Comcast

$37.07

-0.11 (-0.30%)

CMCSK

Comcast

SNE

Sony

$46.20

0.1 (0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANF

Abercrombie & Fitch

$15.49

2.9398 (23.42%)

11:50
11/17/17
11/17
11:50
11/17/17
11:50
Recommendations
Abercrombie & Fitch analyst commentary  »

Abercrombie & Fitch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Nov

HFWA

Heritage Financial

$30.60

0.3 (0.99%)

11:48
11/17/17
11/17
11:48
11/17/17
11:48
Hot Stocks
Heritage Financial, Puget Sound Bancorp deal receives regulatory approvals »

Heritage Financial, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EEM

MSCI Emerging Markets Index

$46.81

0.215 (0.46%)

11:40
11/17/17
11/17
11:40
11/17/17
11:40
Options
108K iShares Emerging Markets Fund Dec 44.5 puts bought for 22c »

108K iShares Emerging…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:35
11/17/17
11/17
11:35
11/17/17
11:35
General news
Euro$ interest rate futures recovered from lows »

Euro$ interest rate…

ANF

Abercrombie & Fitch

$16.00

3.45 (27.49%)

11:31
11/17/17
11/17
11:31
11/17/17
11:31
Downgrade
Abercrombie & Fitch rating change  »

Abercrombie & Fitch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Nov

M

Macy's

$20.63

0.38 (1.88%)

11:30
11/17/17
11/17
11:30
11/17/17
11:30
Options
Calendar risk reversal in Macys may roll call gains into put protection »

Calendar risk reversal in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

ANF

Abercrombie & Fitch

$15.94

3.39 (27.01%)

11:28
11/17/17
11/17
11:28
11/17/17
11:28
Downgrade
Abercrombie & Fitch rating change  »

Abercrombie & Fitch…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Nov

AAPL

Apple

$171.10

2.02 (1.19%)

11:24
11/17/17
11/17
11:24
11/17/17
11:24
Periodicals
Apple delays release of HomePod to early 2018, TechCrunch reports »

Apple is delaying the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$110.15

-0.87 (-0.78%)

, MA

MasterCard

$148.53

-1.7995 (-1.20%)

11:23
11/17/17
11/17
11:23
11/17/17
11:23
Recommendations
Visa, MasterCard analyst commentary  »

Visa highlights possible…

V

Visa

$110.15

-0.87 (-0.78%)

MA

MasterCard

$148.53

-1.7995 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 29

    Nov

GLD

SPDR Gold Trust

$122.32

0.92 (0.76%)

11:20
11/17/17
11/17
11:20
11/17/17
11:20
Options
Far downside put buyers in SPDR Gold ETF as the metal trades higher »

Far downside put buyers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

11:17
11/17/17
11/17
11:17
11/17/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.